Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13798685 | 0.87 | PIM1 (0.34) | KMT2AMEN1KDM4EPPARG | |
| SCHEMBL13798687 | 0.76 | CYP1A2 (0.30) | KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1229639 | 0.73 | SRC (0.36) | KMT2AMEN1KDM4EKEAP1NFE2L2 | |
| SCHEMBL13798680 | 0.72 | CYP1A2 (0.39) | KMT2AKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL2226205 | 0.67 | MEN1 (0.60) | KMT2AMEN1KDM4EKEAP1NFE2L2 | |
| SCHEMBL282501 | 0.67 | SMN1; SMN2 (0.47) | KMT2AMEN1PPARGALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL10559938 | 0.66 | MEN1 (0.58) | KMT2AMEN1KDM4EALDH1A1HPGD | |
| SCHEMBL22554085 | 0.66 | KDM4C (0.40) | KMT2AMEN1KDM4EALDH1A1CYP2C9 | |
| SCHEMBL21996593 | 0.64 | CDK5 (0.39) | KMT2AMEN1KDM4EPPARGKEAP1 | |
| SCHEMBL26979235 | 0.64 | KMT2A (0.37) | KMT2AMEN1KDM4EPPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | HSP90AA1, HSP90AB1, RAF1 | KMT2A 1962/4885MEN1 4350/4885KDM4E 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.